Survey - Australian Urologist’s Attitudes to Prescribing ARPIs
Members are invited to participate in a survey regarding urologists’ prescribing attitudes towards Androgen Receptor Pathway Inhibitors (ARPIs).
The management of mHSPC has evolved dramatically over the last decade. There has been a shift in the treatment paradigm towards earlier treatment intensification with ARPIs: apalutamide, enzalutamide and darolutamide.
A team at Austin Health, led by USANZ Member A/Prof Joseph Ischia, is currently assessing urologists’ attitudes and perceived limitations to the use of ARPIs in the management of mHSPC.
An initial survey will assess current prescribing patterns and barriers to prescription of ARPIs. For those interested, this will be followed by a brief educational dinner (non-pharma sponsored) or workshop to address the identified barriers and a follow-up survey immediately and 6 months after the event to analyse change in confidence related to prescription of ARPIs.
The research has been approved by the Austin Health Human Research Ethics Committee.
For more information, download the Invitation to Participate.